A Phase 1 Study to Determine the Safety and Biological Activity of Cell-Mediated Gene Therapy Using TissueGene-C in Patients With Degenerative Joint Disease Prior to Total Knee Arthroplasty
Phase of Trial: Phase I
Latest Information Update: 26 Nov 2018
Price : $35 *
At a glance
- Drugs Tonogenchoncel-L (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions; First in man
- Sponsors Kolon TissueGene; TissueGene
- 16 Mar 2018 According to a Kolon TissueGene media release, TissueGene changed its name to Kolon TissueGene.
- 29 Jun 2016 Time frame of primary end point changed from Days 0, 3, 7, 11, 28, 29 and at 3, 6, 9, and 12 months following dosing to through 28 days post-dosing.
- 18 Sep 2014 New trial record